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•  Immunotherapy	   consists	   of	   the	   use	   of	   immunologic	   principles	   against	   tumours.	   Unlike	   chemotherapy	   or	   radiotherapy,	   immunotherapy	   has	   the	  
poten<al	  to	  induce	  such	  a	  dynamic	  immune	  response	  that	  can	  kill	  tumour	  cells	  for	  an	  extended	  period	  of	  <me.	  
•  The	  use	  of	   chimeric	  an<gen	   receptors	   (CARs)	   in	   lymphocytes	   is	   an	  emerging	   immunotherapy	  approach.	  These	   receptors	  bind	   to	   tumour-­‐speciﬁc	  
an<gens,	  promo<ng	  the	  ac<va<on	  of	  the	  host’s	  immune	  cells,	  which	  results	  in	  a	  speciﬁc	  immune	  response	  against	  tumour	  cells.	  
Materials	  and	  Methods	  
•  Search	  of	  scien/ﬁc	  literature	  in	  PubMed:	  reviews	  and	  recent	  papers	  about	  CARs	  and	  their	  use	  in	  pre-­‐clinical	  and	  clinical	  trials	  were	  selected.	  
•  Use	  of	  Immunology	  books:	  reading	  of	  the	  chapters	  concerning	  T-­‐cell	  ac<va<on,	  an<gen	  receptors,	  immune	  responses	  and	  autoimmunity.	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Considera<ons	   for	   the	   improvement	   of	   CARs	   in	   terms	   of	   eﬃcacy	  
increase	  and	  toxicity	  decrease:	  
•  It	   is	   extremely	   important	   to	   use	   tumour-­‐restricted	   an<gens	   in	   order	   to	  
decrease	  toxicity	  and	  oﬀ-­‐target	  eﬀects.	  	  
	  •  Suggested	   measurements	   to	   decrease	   the	   likelihood	   of	   genera<ng	  
autoimmune	  reac<ons:	  
	   o  SpliXng	  the	  modiﬁed	  T-­‐cell	  doses.	  	  
o  Introducing	  suicidal	  genes	  into	  the	  CARs	  construct.	  These	  genes	  get	  ac<vated	  
in	  highly	  toxic	  environments,	  promo<ng	  the	  apoptosis	  of	  the	  modiﬁed	  T-­‐cells.	  
	  •  Economic	   and	   logis<c	   costs:	   the	   modiﬁca<on	   of	   T-­‐cells	   is	   performed	   for	  
each	  individual’s	  T-­‐cells.	  The	  use	  of	  allogeneic	  lymphocytes	  is	  an	  alterna<ve	  




•  B-­‐cell	  malignancies	  are	  the	  cancer	  types	  in	  which	  the	  use	  of	  CARs	  has	  
provided	  the	  best	  outcomes	  and	  CD19	  is	  the	  most	  successful	  target.	  
•  The	  success	  of	  this	  approach	  relies	  on	  the	  development	  of	  modiﬁed	  	  
T-­‐cells	  able	  to	  overcome	  the	  hos<le	  tumour	  microenvironment	  and	  to	  
promote	  eﬃcient	  and	  accurate	  cognate	  immune	  responses.	  	  
•  An/gen-­‐binding	  extracellular	  domain:	  binding	  site	  of	  the	  an<body	  that	  targets	  
the	  cognate	  an<gen.	  
•  Trans-­‐membrane	  domain	  
•  Signal-­‐ac/va/ng	  intracellular	  domain:	  	   1st	  genera<on:	  no	  co-­‐s<mulatory	  
molecules.	  o  S<mulatory	  molecule:	  CD3	  ζ	  chain	  
o  Co-­‐s<mulatory	  molecule:	  CD28,	  4-­‐1BB…	   2nd	  genera<on:	  1	  co-­‐s<mulatory	  
molecule.	  
3rd	  genera<on:	  2	  or	  more	  co-­‐s<mulatory	  
molecules.	  
Table	  provided	  by	  the	  author.	  
Steps	  for	  lymphocyte	  modiﬁca/on:	  
1.	  Apheresis:	  separa<on	  of	  T-­‐cells	  from	  the	  rest	  of	  blood	  cell	  types.	  
2.	  Internaliza/on	  of	  CAR	  constructs	  into	  T-­‐cells.	  Strategies:	  	  
a.	  Electropora<on	  
b.	  Viral	  vectors:	  most	  used	  strategy	  	  
c.	  Transposon-­‐based	  systems	  	  
3.	  Expansion	  of	  T-­‐cells	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  muta<on	  rate	  
Ac<va<ng	  signals:	  An<-­‐CD3	  ac<va<ng	  monoclonal	  an<body	  






4.	  Transfusion	  of	  an	  op/mal	  number	  of	  modiﬁed	  T-­‐cells	  	  
back	  to	  the	  pa/ent.	  
